Cholestyramine Resin and Valproate sodium Intravenous
Determining the interaction of Cholestyramine Resin and Valproate sodium Intravenous and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Cholestyramine may interfere with the absorption of valproic acid and reduce its effectiveness in treating your condition. You should take cholestyramine and valproic acid at least 3 hours apart. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
Professional:ADJUST DOSING INTERVAL: Cholestyramine may interfere with the gastrointestinal absorption of valproic acid and reduce its bioavailability. In six study subjects, administration of a single 250 mg dose of valproic acid simultaneously with a 4 gram dose of cholestyramine (given twice daily starting one day before valproic acid administration) resulted in an average 15% decrease in valproic acid peak serum concentration and 21% decrease in systemic exposure (AUC) compared to administration alone. By contrast, no significant interaction was observed when valproic acid was given 3 hours before the cholestyramine dose. The bioavailability of valproic acid, relative to administration alone, was 86.2% when given concurrently with cholestyramine and 95.3% when given 3 hours before cholestyramine.
MANAGEMENT: To minimize potential for interaction, valproic acid and cholestyramine should be administered at least 3 hours apart. Patients should be monitored for clinical and laboratory evidence of altered valproate efficacy, and the dosage adjusted if necessary. It is not known whether these precautions are applicable to extended-release valproic acid or divalproex formulations.
- "Product Information. Depakene (valproic acid)." Abbott Pharmaceutical, Abbott Park, IL.
- Malloy MJ, Ravis WR, Pennell AT, Diskin CJ "Effect of cholestyramine resin on single dose valproate pharmacokinetics." Int J Clin Pharmacol Ther 34 (1996): 208-11
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: cholestyramine
Brand name: Cholestyramine Light, Prevalite, Questran, Questran Light, Locholest, Locholest Light, Questran Light Packets, Prevalite Packets, Questran Packets
Synonyms: Cholestyramine
Generic Name: valproic acid
Brand name: Depakene, Depacon, Stavzor, Valproate Sodium
Synonyms: Valproate sodium (Intravenous)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cholestyramine Resin-Valproic acid
- Cholestyramine Resin-Valproic Acid and Derivatives
- Cholestyramine Resin-Valproic Acid Capsules
- Cholestyramine Resin-Valproic Acid Liquid
- Cholestyramine Resin-Valproic Acid Oral Solution
- Cholestyramine Resin-Valproic Acid Syrup
- Valproate sodium Intravenous-Choletec
- Valproate sodium Intravenous-Cholic acid
- Valproate sodium Intravenous-Choline magnesium trisalicylate
- Valproate sodium Intravenous-Choline Magnesium Trisalicylate Liquid
- Valproate sodium Intravenous-Cholografin Meglumine
- Valproate sodium Intravenous-Chondroitin